Department of Sports Medicine, Goethe University, Frankfurt am Main, Germany.
Int J Sports Med. 2013 Jul;34(7):631-6. doi: 10.1055/s-0032-1323746. Epub 2013 Feb 26.
The present study evaluated the validity of the six-minute walk test (6MWT) in cancer patients. 50 subjects (36 f, 14 m; 57.4±10.2 years; during (56%) or off (44%) cancer treatment) performed a 6MWT and a spiroergometry on a cycle ergo-meter (0+25 W, 3 min) to evaluate maximum exercise capacity (VO2peak). A subsample (n=30) completed a retest of the 6MWT within 2-7 days. Patients covered a distance of 594±81 m during 6MWT at an average intensity of 86.3±9.6% of HRmax and achieved a VO2peak of 21.2±4.86 ml · kg - 1 · min - 1 during cycle ergometry. The distance walked correlated significantly (p<0.001) with VO2peak (r=0.67) and perceived physical function (EORTC QLQ-C30 physical function subscale) (r=0.55). Concerning reliability the intraclass correlation coefficient was r=0.93 (95%CI: +0.86;+0.97; p<0.001) and the coefficient of variation 3%. During retest participants walked 3.1% (95%CI: +1.1; +5.2) farther and achieved a higher RPE (+1.0; 95%CI: +0.3;+1.8). Limits of agreement were between - 43.1 and 76.4 m. In cancer patients the 6MWT seems to be as valid and reliable as in healthy elderly, cardiac and pulmonary patients. Thus, it can be recommended for use in cancer patients.
本研究评估了六分钟步行试验（6MWT）在癌症患者中的有效性。50 名受试者（36 名女性，14 名男性；57.4±10.2 岁；正在接受（56%）或已结束（44%）癌症治疗）进行了 6MWT 和在功率自行车上进行的心肺运动试验（0+25 W，3 分钟），以评估最大运动能力（VO2peak）。一个亚组（n=30）在 2-7 天内完成了 6MWT 的复测。患者在 6MWT 中平均强度为 HRmax 的 86.3±9.6%时行走了 594±81 m，在功率自行车上达到了 21.2±4.86 ml·kg-1·min-1的 VO2peak。行走距离与 VO2peak 显著相关（p<0.001）（r=0.67）和感知的身体功能（EORTC QLQ-C30 身体功能子量表）（r=0.55）。关于可靠性，组内相关系数为 r=0.93（95%CI：+0.86；+0.97；p<0.001），变异系数为 3%。在复测中，参与者多走了 3.1%（95%CI：+1.1；+5.2），达到了更高的 RPE（+1.0；95%CI：+0.3；+1.8）。一致性界限在-43.1 到 76.4 m 之间。在癌症患者中，6MWT 似乎与健康老年人、心脏和肺部患者一样有效且可靠。因此，它可以推荐用于癌症患者。
